Jiska van Schaik1,2, Dominique G A Begijn3, Laura van Iersel3, Yvonne Vergeer3,4, Eelco W Hoving5, Babette Peeters6, Hanneke M van Santen3,7. 1. Division of Pediatric Endocrinology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands, j.vanschaik-3@umcutrecht.nl. 2. Princess Máxima Center, Utrecht, The Netherlands, j.vanschaik-3@umcutrecht.nl. 3. Division of Pediatric Endocrinology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands. 4. Diabetes Centraal, St Antonius Hospital, Utrecht, The Netherlands. 5. Department of Neurooncology, Princess Máxima Center, Utrecht, The Netherlands. 6. Department of Pediatrics, Meander Medical Center, Utrecht, The Netherlands. 7. Princess Máxima Center, Utrecht, The Netherlands.
Abstract
OBJECTIVE: Hypothalamic obesity (HO) in children after treatment for a tumor in the suprasellar region has severe implications. Previous studies have shown various effects of glucagon-like peptide-1 (GLP-1) receptor agonist in acquired HO, but in adults only. We present our experience of GLP-1 receptor agonist (exenatide) treatment during a 1-year period on body mass index (BMI) in children with acquired HO. PATIENTS AND METHODS: Children with severe weight gain after treatment for suprasellar tumor were given 2 mg exenatide weekly for a 12-month period. All had undergone previous dietary intervention. BMI standard deviation score (SDS), weight change, and adverse effects were assessed. RESULTS: Five children with a mean age of 15.4 years (range 13-18) and a mean follow-up time of 8.4 years (mean age of 7.0 years at the time of brain tumor diagnosis) were treated with GLP-1 receptor agonist. After 1 year, BMI SDS or absolute weight had not changed significantly compared to the period without treatment (BMI SDS change +0.005, 95% CI -0.07 to 0.08, p = 0.89, and absolute weight change +1.5 kg, 95% CI -0.08 to 3.1, p = 0.061). Only 1 patient experienced weight loss after 1 year (-5.4 kg, BMI SDS -0.33). All patients experienced mild side effects, such as injection pain or nausea, and 2 patients stopped treatment upon their own request after 8 and 11 months, respectively. CONCLUSIONS: In this small cohort, we found little effect of GLP-1 receptor agonist in the treatment for acquired HO. Future research should focus on the prevention of HO or, if prevention is not possible, on alternative, individualized interventions.
OBJECTIVE:Hypothalamic obesity (HO) in children after treatment for a tumor in the suprasellar region has severe implications. Previous studies have shown various effects of glucagon-like peptide-1 (GLP-1) receptor agonist in acquired HO, but in adults only. We present our experience of GLP-1 receptor agonist (exenatide) treatment during a 1-year period on body mass index (BMI) in children with acquired HO. PATIENTS AND METHODS: Children with severe weight gain after treatment for suprasellar tumor were given 2 mg exenatide weekly for a 12-month period. All had undergone previous dietary intervention. BMI standard deviation score (SDS), weight change, and adverse effects were assessed. RESULTS: Five children with a mean age of 15.4 years (range 13-18) and a mean follow-up time of 8.4 years (mean age of 7.0 years at the time of brain tumor diagnosis) were treated with GLP-1 receptor agonist. After 1 year, BMI SDS or absolute weight had not changed significantly compared to the period without treatment (BMI SDS change +0.005, 95% CI -0.07 to 0.08, p = 0.89, and absolute weight change +1.5 kg, 95% CI -0.08 to 3.1, p = 0.061). Only 1 patient experienced weight loss after 1 year (-5.4 kg, BMI SDS -0.33). All patients experienced mild side effects, such as injection pain or nausea, and 2 patients stopped treatment upon their own request after 8 and 11 months, respectively. CONCLUSIONS: In this small cohort, we found little effect of GLP-1 receptor agonist in the treatment for acquired HO. Future research should focus on the prevention of HO or, if prevention is not possible, on alternative, individualized interventions.
Authors: Aaron S Kelly; Andrea M Metzig; Kyle D Rudser; Angela K Fitch; Claudia K Fox; Brandon M Nathan; Mary M Deering; Betsy L Schwartz; M Jennifer Abuzzahab; Laura M Gandrud; Antoinette Moran; Charles J Billington; Sarah J Schwarzenberg Journal: Obesity (Silver Spring) Date: 2011-11-10 Impact factor: 5.002
Authors: S K Thondam; D J Cuthbertson; B S Aditya; I A Macfarlane; J P Wilding; C Daousi Journal: Clin Endocrinol (Oxf) Date: 2012-10 Impact factor: 3.478
Authors: Jill K Hamilton; Louise S Conwell; Catriona Syme; Alexandra Ahmet; Allison Jeffery; Denis Daneman Journal: Int J Pediatr Endocrinol Date: 2011-03-22
Authors: Yvonne Schönbeck; Henk Talma; Paula van Dommelen; Boudewijn Bakker; Simone E Buitendijk; Remy A HiraSing; Stef van Buuren Journal: Pediatr Res Date: 2012-12-10 Impact factor: 3.756
Authors: Yvonne Schönbeck; Henk Talma; Paula van Dommelen; Boudewijn Bakker; Simone E Buitendijk; Remy A Hirasing; Stef van Buuren Journal: PLoS One Date: 2011-11-15 Impact factor: 3.240
Authors: Hermann L Müller; Maithé Tauber; Elizabeth A Lawson; Jale Özyurt; Brigitte Bison; Juan-Pedro Martinez-Barbera; Stephanie Puget; Thomas E Merchant; Hanneke M van Santen Journal: Nat Rev Dis Primers Date: 2022-04-21 Impact factor: 52.329
Authors: Jiska van Schaik; Mila S Welling; Corjan J de Groot; Judith P van Eck; Alicia Juriaans; Marcella Burghard; Sebastianus B J Oude Ophuis; Boudewijn Bakker; Wim J E Tissing; Antoinette Y N Schouten-van Meeteren; Erica L T van den Akker; Hanneke M van Santen Journal: Front Endocrinol (Lausanne) Date: 2022-03-09 Impact factor: 5.555